title: Nanobodies and their Use in GPCR Drug Discovery.
abstract: Nanobodies are therapeutic proteins derived from the variable domain (VHH) of naturally occurring heavy-chain antibodies. These VHH domains are the smallest functional fragments derived from a naturally occurring immunoglobulin. Nanobodies can be easily produced in prokaryotic or eukaryotic host organisms and their unique biophysical characteristics render these molecules ideal candidates for drug development. They are also emerging as an interesting new class of potential therapeutics for targets such as GPCRs, which have historically been challenging for small molecule drug discovery and even more difficult for biologics discovery. The ability to easily combine Nanobodies with different binding sites and different modes of action can be used to generate highly selective and highly potent drug candidates with very attractive pharmacological profiles. In addition, Nanobodies have been used as crystallization chaperones to enable or facilitate the structural determination of an active GPCR conformation.
authors.forename: Karen D
authors.initials: KD
authors.lastname: Cromie
authors.forename: Gino
authors.initials: G
authors.lastname: Van Heeke
authors.affiliation: Ablynx NV, Technologiepark 21, B-9052 Zwijnaarde, Belgium. carlo.boutton@ablynx.com.
authors.forename: Carlo
authors.initials: C
authors.lastname: Boutton
mesh_terms: D000818:Animals; D001665:Binding Sites; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D061905:Single-Domain Antibodies / Q000378:metabolism*
chemical_list: D043562:Receptors, G-Protein-Coupled; D061905:Single-Domain Antibodies